EN | UA
EN | UA

Help Support

Back

Consequences of methotrexate (MTX) on the efficacy of tofacitinib in RA patients

Consequences of methotrexate (MTX) on the efficacy of tofacitinib in RA patients Consequences of methotrexate (MTX) on the efficacy of tofacitinib in RA patients
Consequences of methotrexate (MTX) on the efficacy of tofacitinib in RA patients Consequences of methotrexate (MTX) on the efficacy of tofacitinib in RA patients

What's new?

In RA patients, tofacitinib has been found to be clinically effective at different doses, notwithstanding the background MTX dose.

Tofacitinib is a drug of the janus kinase inhibitor class used for rheumatoid arthritis (RA) treatment. This is an post hoc analysis which estimated the effect of methotrexate (MTX) dose on the efficacy of tofacitinib in patients suffering from RA.

This ORAL Scan (NCT00847613) was a 2-year, randomized, Phase 3 trial investigating tofacitinib in MTX-inadequate responder (IR) patients with RA.

The patients were given tofacitinib 5 or 10 mg twice daily (BID), or placebo, with low (≤12.5 mg/week), moderate (>12.5 to <17.5 mg/week), or high (≥17.5 mg/week) firm background MTX.

At months 3 and 6, the efficacy endpoints encompassed  American College of Rheumatology (ACR) 20/50/70 response rates, and mean change from baseline in Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28)–4(erythrocyte sedimentation rate [ESR]), Health Assessment Questionnaire-Disability Index (HAQ-DI), and altered Total Sharp score.

A total of 797 patients were included in this analysis with tofacitinib 5 mg BID (N = 321), tofacitinib 10 mg BID (N = 316), or placebo (N = 160). Low MTX doses were given to 242 patients, moderate MTX doses to 333 patients and high MTX doses to 222 patients.

Across all MTX doses, ACR20/50/70 response rates were greater for both tofacitinib doses vs placebo at months 3 and 6. The mean changes from baseline in CDAI and HAQ-DI were notably greater for both tofacitinib doses vs placebo, irrespective of MTX category at month 3. Stablity was observed in imrovements at month 6.

Across MTX doses at month 6, both the tofacitinib doses revealed improvements in DAS28–4(ESR) and less structural progression vs placebo.

Hence, regardless of MTX dose, tofacitinib plus MTX portrayed greater clinical and radiographic efficacy than placebo in MTX-IR patients with RA.

Source:

Clinical Rheumatology

Article:

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group

Authors:

R Fleischmann et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: